Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-50002 in Alopecia Areata
NCT03354637Phase 2Terminated
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Nov 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifidancitinib in alopecia areata, sponsored by Aclaris Therapeutics, Inc.. Started Nov 2017; status: terminated.
02
Drugs
ifidancitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT03354637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03354637.